Skip to main content
  • COVID-19
    • COVID-19 vaccines and cancer
      • FAQs
      • FAQs in-language
      • SerOzNET Study
    • COVID-19 information for people affected by cancer
      • Managing your cancer care in the context of COVID-19
      • Looking after your mental wellbeing
      • Canada
      • Ireland
      • UK
      • USA
    • COVID-19 information for children and young people with cancer
    • Cancer Won’t Wait
    • Cancer and COVID-19 - what it means for our Mob
      • COVID-19 vaccines: Information for Aboriginal and Torres Strait Islander people affected by cancer
      • Act early for our Mob's health
    • Guidance for health professionals
      • Diagnosis
      • Treatment
      • Surgery
      • Medical oncology
      • Radiation oncology
      • Primary care
      • Telehealth
      • Clinical trials
      • Follow-up care
      • Supportive and Palliative care
      • Cancer care for cancer patients with COVID-19
      • COVID-19 vaccines and cancer
      • Recovery
    • Research articles
      • Review articles
      • Data articles
      • Recommendations articles
      • Shared experience articles
      • COVID-19 vaccines and cancer articles
    • Cancer care in the time of COVID-19: A conceptual framework
    • Optimal cancer care during the COVID-19 pandemic: the Principles
    • The impact of COVID-19 on cancer services
    • COVID-19 Recovery: Implications for cancer care
      • Expanded use of telehealth
      • Changes to prevention and early detection
      • Virtual multidisciplinary team meetings
      • Modifications to treatment schedules
      • Hypofractionated radiotherapy
      • Oncology hospital in the home
      • Responsive patient support
      • Innovative care and hospital infrastructure models
      • Shared follow-up and survivorship care
      • Supportive and palliative care
      • Cancer research and clinical trials
      • Collaboration in the oncology sector and data sharing
      • Acknowledgements
  • About us
    • Organisational structure
    • Accountability and reporting
      • Annual reports
    • Who we work with
      • Roles & functions
      • Advisory Council
      • Advisory groups
      • Consumer engagement
      • Government cancer control organisations
    • Information publication scheme
      • Information publication scheme plan
      • Freedom of information act
        • The FOI request process
      • FOI disclosure log
    • Reconciliation action plan
    • Employment opportunities
  • News and media
    • News
    • Subscribe to our eNewsletter
  • Contact us
Cancer Australia
Choose Language
  • العربية
  • 简体中文
  • 繁體中文
  • Ελληνικά
  • हिन्दी
  • Italiano
  • 한국어
  • Español
  • Tagalog
  • Tiếng Việt
  • العربية
  • 简体中文
  • 繁體中文
  • Ελληνικά
  • हिन्दी
  • Italiano
  • 한국어
  • Español
  • Tagalog
  • Tiếng Việt
  • العربية
  • 简体中文
  • 繁體中文
  • Ελληνικά
  • हिन्दी
  • Italiano
  • 한국어
  • Español
  • Tagalog
  • Tiếng Việt
  • Home
  • Cancer types
  • Impacted by Cancer
  • Awareness
  • Research
  • Resources
  • Clinicians hub
  • Key initiatives
  • Home
  • Cancer types
    • Bladder cancer
    • Bowel cancer
    • Brain cancer
    • Breast cancer
    • Breast cancer in men
    • Breast cancer in young women
    • Cervical cancer
    • Children’s cancer
    • Endometrial cancer
    • Fallopian cancer
    • Gestational trophoblastic disease
    • Gynaecological cancers
    • Head and neck cancer
    • Kidney cancer
    • Leukaemia
    • Liver cancer
    • Lung cancer
    • Lymphoma
    • Melanoma
    • Mesothelioma cancer
    • Myeloma
    • Neuroendocrine tumours
    • Oesophageal cancer
    • Ovarian cancer
    • Pancreatic cancer
    • Prostate cancer
    • Sarcoma
    • Stomach cancer
    • Testicular cancer
    • Thyroid cancer
    • Unknown primary cancer
    • Uterine sarcoma
    • Vaginal cancer
    • Vulvar cancer
  • Impacted by Cancer
    • What is cancer
    • Physical changes
    • Treatment
    • Keeping healthy
    • Emotions
    • Family and relationships
    • Living with cancer
    • Lynch Syndrome
  • Awareness
    • Your cancer risk
    • Screening
    • Interactive body map
  • Research
    • Cancer Research in Australia
    • Data and statistics
    • Australian Clinical Trials
    • Support for cancer clinical trials
    • Grants and funding
  • Resources
    • Cancer Australia Publications
    • Clinical Practice Guidelines
    • Position statements
    • Resources in other languages
    • Cancer Australia websites
    • Cancer risk online assessment tools
    • Other tools and resources
    • Podcasts
    • Cancer support organisations
    • Glossary
  • Clinicians hub
    • GP guides and resources
    • Guidelines by cancer type
    • Optimal Care pathways
    • Working with Aboriginal and Torres Strait Islander people
    • Multidisciplinary care
    • Psychosocial care
    • Follow-up care
    • Family cancer clinics
    • Cancer Learning
    • Consumer engagement
  • Key initiatives
    • For Aboriginal and Torres Strait Islander people
    • Australian Cancer Plan
    • Australian Brain Cancer Mission
    • Lung Cancer Screening
    • National Pancreatic Cancer Roadmap
    • Campaigns & events
    • Jeannie Ferris Recognition Award

Fallopian cancer

fallopian-mm cancer-types/fallopian-cancer/overview
    • Home
    • Types
    • Statistics
    • Risk factors
    • Symptoms
    • Diagnosis
    • Screening
    • Treatment
      • Effects on fertility
    • Living with
    • Finding support
    • Clinical trials
    • Health professionals
    • Home
    • Types
    • Statistics
    • Risk factors
    • Symptoms
    • Diagnosis
    • Screening
    • Treatment
      • Effects on fertility
    • Living with
    • Finding support
    • Clinical trials
    • Health professionals
  1. Home
  2. Statistics
Loading...

Fallopian tube cancer statistics

  • Printer-friendly version
  • A|A

The following material has been sourced from the Australian Institute of Health and Welfare

Gynaecological cancer incorporates ICD-10 cancer codes C51 (Malignant neoplasm of vulva), C52 (Malignant neoplasm of vagina), C53 (Malignant neoplasm of cervix), C54 (Malignant neoplasm of corpus uteri), C55 (Malignant neoplasm of uterus, part unspecified), C56 (Malignant neoplasm of ovary), C57 (Malignant neoplasm of other and unspecified female genital organs) and C58 (Malignant neoplasm of placenta).


Estimated number of new cases of gynaecological cancer diagnosed in 2021

female icon6,576 females


Estimated % of all new female cancer cases diagnosed in 2021

9.3%


Estimated number of deaths from gynaecological cancer in 2021

female icon2,139 females


Estimated % of all female deaths from cancer in 2021

9.9%


Chance of surviving at least 5 years (2013–2017)

71%


Females living with gynaecological cancer at the end of 2016 (diagnosed in the 5 year period 2012 to 2016)

21,087


New cases

In 2017, gynaecological cancer as a group represents 9.3% of cancers diagnosed in women and the most common gynaecological cancer was uterine cancer (see details on the uterine cancer page).

In 2017, there were 5,823 new cases of gynaecological cancers diagnosed in Australia. In 2021, it is estimated that 6,576 new cases of gynaecological cancers will be diagnosed in Australia. In 2021, it is estimated that a female has a 1 in 23 (or 4.4%) risk of being diagnosed with a gynaecological cancer by the age of 85.

 

Figure 1. Estimated most common cancers diagnosed among females, 2021

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2021 web report and supplementary data tables
  • More information about incidence rates for the most common cancers diagnosed can be found on the NCCI website in the ‘Cancer incidence’ section (https://ncci.canceraustralia.gov.au/diagnosis/cancer-incidence/cancer-incidence)

In 2017, the age-standardised incidence rate was 41 cases per 100,000 females. In 2021, it is estimated that the age-standardised incidence rate will be 42 cases per 100,000 females. The incidence rate for gynaecological cancers is expected to increase with age, peaking at age group 75–79 years.

Figure 2. Age-standardised incidence rates for gynaecological cancers, 1982 to 2017

Notes: Data sourced from AIHW Cancer Data in Australia 2021 web report and supplementary data tables 

The number of new cases of gynaecological cancers diagnosed increased from 2,951 in 1982 to 5,823 in 2017. Over the same period, the age-standardised incidence rate decreased from 44 cases per 100,000 females in 1982 to 41 cases per 100,000 females in 2017.

Deaths 

In 2019, gynaecological cancer as a group represents 10% of cancer related deaths in women and ovarian cancer was the most common cause of gynaecological cancer-related death. 

In 2019, there were 2,150 deaths from gynaecological cancers in Australia. In 2021, it is estimated that there will be 2,139 deaths. In 2021, it is estimated that a female has a 1 in 71 (or 1.4%) risk of dying from a gynaecological cancer by the age of 85.

Figure 3. Estimated most common causes of cancer death among females, 2021

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2021 web report and supplementary data tables
  • More information about mortality rates for the most common causes of cancer death can be found on the NCCI website in the ‘Cancer mortality’ section (https://ncci.canceraustralia.gov.au/outcomes/cancer-mortality/cancer-mortality)

In 2019, the age-standardised mortality rate was 13 deaths per 100,000 females. In 2021, it is estimated that the age-standardised mortality rate will remain 13 deaths per 100.000 females). The mortality rate for gynaecological cancer is expected to increase with age.

Mortality rates for fallopian cancer

Figure 4. Age-standardised mortality rates for gynaecological cancers, 1982 to 2019

Note: Data sourced from AIHW Cancer Data in Australia 2021 web report and supplementary data tables

The number of deaths from gynaecological cancers increased from 1,235 in 1982 to 2,150 in 2019. Over the same period, the age-standardised mortality rate decreased from 19 deaths per 100,000 females in 1982 to 13 deaths per 100,000 in 2019. 

Survival 

In 2013–2017, females diagnosed with gynaecological cancers had a 71% chance of surviving for at least five years compared to their counterparts in the general Australian population. Between 1988–1992 and 2013–2017, five-year relative survival for gynaecological cancers improved from 63% to 71%.

Figure 5. 5-year relative survival for gynaecological cancers, 1988–1992 to 2013–2017

Notes: Data sourced from AIHW Cancer Data in Australia 2021 web report and supplementary data tables

Prevalence 

At the end of 2016, there were 5,283 females living who had been diagnosed with gynaecological cancers that year, 21,087 females living who had been diagnosed with gynaecological cancers in the previous 5 years (from 2012 to 2016) and 65,764 females living who had been diagnosed with gynaecological cancers in the previous 35 years (from 1982 to 2016).

For more information on cancer data, see the NCCI website  

The National Cancer Control Indicators (NCCI) are a set of indicators across the continuum of cancer care, from Prevention and Screening through to Diagnosis, Treatment, Psychosocial care, Research and Outcomes.  The NCCI website allows users to see visual representations of data on each indicator through interactive charts. 

  • Last Updated
  • Relevant Links
updated: 17 September 2021 - 5:09pm
Australian Cancer Research Foundation, Gynaecological cancer
National Cancer Institute (US), Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment (PDQ®), patient vers
Australian Cancer Trials
Rare Cancers Australia

Related information

What is cancer?
What is cancer?

Cancer is a disease of the cells, which are the body’s basic building blocks.

Treatment and side effects
Treatment and side effects

The treatment that your doctors recommend will depend on the type of cancer you have, how advanced it is, and other personal factors.

Living with cancer
Living with cancer

A diagnosis of cancer marks the beginning of a journey full of emotional, psychological, physical and practical challenges.

Life after cancer
Life after cancer

While looking forward to finishing their cancer treatment and getting on with life, for some people, the end of treatment can also be a confusing or worrying time.

A-Z List of Cancer Types

Information on more than 70 types of cancer

  • Bladder cancer
  • Bowel cancer
  • Brain cancer
  • Breast cancer
  • Breast cancer in men
  • Breast cancer in young women
  • Cervical cancer
  • Children's Cancer
  • Endometrial cancer
  • Fallopian cancer
  • Gestational trophoblastic disease
  • Gynaecological cancers
  • Head and neck cancer
  • Kidney cancer
  • Leukaemia
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Melanoma of the skin
  • Mesothelioma cancer
  • Myeloma
  • Neuroendocrine tumours
  • Oesophageal cancer
  • Ovarian cancer
  • Pancreatic cancer
  • Prostate cancer
  • Sarcoma
  • Stomach cancer
  • Testicular cancer
  • Thyroid cancer
  • Unknown primary
  • Uterine sarcoma
  • Vaginal cancer
  • Vulval cancer

About Cancer Australia

Cancer Australia was established by the Australian Government in 2006 to benefit all Australians affected by cancer, and their families and carers. Cancer Australia aims to reduce the impact of cancer, address disparities and improve outcomes for people affected by cancer by leading and coordinating national, evidence-based interventions across the continuum of care.

If you would like an interpreter to help you understand any information on this website, please call TIS National on 131 450 and ask them to call Cancer Australia on 02 9357 9400. Our business hours are 9am to 5pm, Monday to Friday.

Freecall 1800 624 973
+61 2 9357 9400

Locked Bag 3, Strawberry Hills
NSW 2012

Navigation

  • Cancer types
  • Impacted by Cancer
  • Awareness
  • Research
  • Resources
  • Clinicians hub
  • Key initiatives

Contact us

* Denotes mandatory fields
 

By submitting this form, you accept the Cancer Australia privacy policy.

  • Contact Us
  • Copyright
  • Disclaimer
  • Privacy policy
  • Sitemap
Copyright © 2023 - Cancer Australia